NasdaqGS:AMRXPharmaceuticals
What Amneal Pharmaceuticals (AMRX)'s Return to Profitability and 2026 Guidance Means For Shareholders
Amneal Pharmaceuticals recently reported fourth-quarter and full-year 2025 results showing sales rising to US$814.32 million for the quarter and US$3.02 billion for the year, alongside a move from a full-year net loss to net income of US$72.06 million and positive earnings per share.
On the same day, the company issued 2026 net revenue guidance of US$3.05 billion to US$3.15 billion, signaling management’s confidence following its return to profitability and ahead of its March 2026...